Acorda First Quarter 2022 Update: Webcast/Conference Call Scheduled for May 11, 2022

Rhea-AI Summary

Acorda Therapeutics (NASDAQ: ACOR) is set to host a webcast and conference call on May 11, 2022, at 4:30 p.m. ET, to discuss its first quarter 2022 update and financial results. Participants can pre-register through the provided link. A replay will be available from 7:30 p.m. ET on the same day until June 10, 2022. Acorda focuses on therapies for neurological disorders, including INBRIJA® and AMPYRA®, utilizing its innovative ARCUS® pulmonary delivery system.

Positive

• Scheduled webcast on May 11 to discuss Q1 2022 results, providing transparency to investors.

Negative

• Risks mentioned include potential adverse effects on product sales due to COVID-19 restrictions.
• The company faces competition and loss of revenues from generic versions of AMPYRA following patent expiration.

ARDSLEY, N.Y.--(BUSINESS WIRE)-- Acorda Therapeutics, Inc. (NASDAQ: ACOR) will host a webcast/conference call in conjunction with its first quarter 2022 update and financial results on Wednesday, May 11 at 4:30 p.m. ET.

To participate in the Webcast, please use the following pre-registration link:

• https://event.on24.com/wcc/r/3723569/6748F9A544568ED252317BCE137DC161

If you register for the Webcast, you will have the opportunity to submit a written question for the Q&A portion of the presentation. Once you have registered, you will receive a confirmation email with Webcast/Conference Call details. For the Webcast, you will receive an email 2 hours prior to the start of the call with the link to join. The presentation will be available on the Investors section of www.acorda.com.

A replay of the call will be available from 7:30 p.m. ET on May 11, 2022 until 11:59 p.m. ET on June 10, 2022. To access the replay, please dial 1 866 813 9403 (domestic) or +44 204 525 0658 (international); reference code 258745. The archived webcast will be available in the Investor Relations section of the Acorda website at www.acorda.com.

About Acorda Therapeutics

Acorda Therapeutics develops therapies to restore function and improve the lives of people with neurological disorders. INBRIJA® (levodopa inhalation powder) is approved for intermittent treatment of OFF episodes in adults with Parkinson’s disease treated with carbidopa/levodopa. INBRIJA is not to be used by patients who take or have taken a nonselective monoamine oxidase inhibitor such as phenelzine or tranylcypromine within the last two weeks. INBRIJA utilizes Acorda’s innovative ARCUS® pulmonary delivery system, a technology platform designed to deliver medication through inhalation. Acorda also markets the branded AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg.

Forward-Looking Statements

This press release includes forward-looking statements. All statements, other than statements of historical facts, regarding management's expectations, beliefs, goals, plans or prospects should be considered forward-looking. These statements are subject to risks and uncertainties that could cause actual results to differ materially, including: we may not be able to successfully market AMPYRA, INBRIJA or any other products under development; the COVID-19 pandemic, including related restrictions on in-person interactions and travel, and the potential for illness, quarantines and vaccine mandates affecting our management, employees or consultants or those that work for other companies we rely upon, could have a material adverse effect on our business operations or product sales; our ability to attract and retain key management and other personnel, or maintain access to expert advisors; our ability to raise additional funds to finance our operations, repay outstanding indebtedness or satisfy other obligations, and our ability to control our costs or reduce planned expenditures; risks associated with the trading of our common stock and our reverse stock split; risks related to our corporate restructurings, including our ability to outsource certain operations, realize expected cost savings and maintain the workforce needed for continued operations; risks associated with complex, regulated manufacturing processes for pharmaceuticals, which could affect whether we have sufficient commercial supply of INBRIJA to meet market demand; our reliance on third-party manufacturers for the production of commercial supplies of AMPYRA and INBRIJA; third-party payers (including governmental agencies) may not reimburse for the use of INBRIJA at acceptable rates or at all and may impose restrictive prior authorization requirements that limit or block prescriptions; reliance on collaborators and distributors to commercialize INBRIJA and AMPYRA outside the U.S.; competition for INBRIJA and AMPYRA, including increasing competition and accompanying loss of revenues in the U.S. from generic versions of AMPYRA (dalfampridine) following our loss of patent exclusivity; the ability to realize the benefits anticipated from acquisitions because, among other reasons, acquired development programs are generally subject to all the risks inherent in the drug development process and our knowledge of the risks specifically relevant to acquired programs generally improves over time; the risk of unfavorable results from future studies of INBRIJA (levodopa inhalation powder) or from other research and development programs, or any other acquired or in-licensed programs; the occurrence of adverse safety events with our products; the outcome (by judgment or settlement) and costs of legal, administrative or regulatory proceedings, investigations or inspections, including, without limitation, collective, representative or class-action litigation; failure to protect our intellectual property, to defend against the intellectual property claims of others or to obtain third-party intellectual property licenses needed for the commercialization of our products; and failure to comply with regulatory requirements could result in adverse action by regulatory agencies.

These and other risks are described in greater detail in our filings with the Securities and Exchange Commission. We may not actually achieve the goals or plans described in our forward-looking statements, and investors should not place undue reliance on these statements. Forward-looking statements made in this press release are made only as of the date hereof, and we disclaim any intent or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release, except as may be required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220504006112/en/

Tierney Saccavino

(914) 326-5104

tsaccavino@acorda.com

Source: Acorda Therapeutics, Inc.

FAQ

When will Acorda Therapeutics present its first quarter 2022 financial results?

Acorda Therapeutics will present its first quarter 2022 financial results during a webcast on May 11, 2022, at 4:30 p.m. ET.

How can I participate in Acorda Therapeutics' upcoming webcast?

You can participate by using the pre-registration link provided in the press release for the webcast on May 11, 2022.

What products does Acorda Therapeutics develop?

Acorda Therapeutics develops therapies for neurological disorders, including INBRIJA® and AMPYRA®.

What are the risks mentioned by Acorda Therapeutics in their press release?

The risks include potential impacts from COVID-19 on product sales and increased competition from generic medications.